Prescott Group Capital Management L.L.C. Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Prescott Group Capital Management L.L.C. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 44.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,500 shares of the medical research company’s stock after purchasing an additional 2,000 shares during the quarter. Prescott Group Capital Management L.L.C.’s holdings in Charles River Laboratories International were worth $1,367,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $298,877,000. Price T Rowe Associates Inc. MD lifted its holdings in Charles River Laboratories International by 35.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock valued at $505,821,000 after buying an additional 653,790 shares in the last quarter. Norges Bank purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $97,675,000. Southpoint Capital Advisors LP bought a new position in shares of Charles River Laboratories International during the 1st quarter worth $80,728,000. Finally, Clearbridge Investments LLC increased its position in Charles River Laboratories International by 28.2% during the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock valued at $388,739,000 after purchasing an additional 301,159 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL traded up $1.76 during trading on Monday, hitting $190.80. The company’s stock had a trading volume of 99,171 shares, compared to its average volume of 528,049. The company has a current ratio of 1.45, a quick ratio of 1.16 and a debt-to-equity ratio of 0.76. The business’s fifty day simple moving average is $188.54 and its 200 day simple moving average is $198.28. The firm has a market capitalization of $9.78 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 2.00 and a beta of 1.35. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $262.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 8th. The medical research company reported $2.72 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.37. Charles River Laboratories International had a net margin of 11.27% and a return on equity of 18.15%. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the company earned $2.63 earnings per share. The company’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $205.00 and set an “equal weight” rating for the company in a research report on Friday, November 10th. TD Cowen decreased their target price on Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating for the company in a report on Monday, September 25th. Evercore ISI cut their price target on shares of Charles River Laboratories International from $235.00 to $225.00 in a report on Wednesday, October 11th. Wells Fargo & Company decreased their price objective on shares of Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, September 22nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $232.54.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster bought 5,620 shares of Charles River Laboratories International stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $178.05 per share, for a total transaction of $1,000,641.00. Following the completion of the transaction, the chief executive officer now directly owns 202,643 shares of the company’s stock, valued at $36,080,586.15. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO James C. Foster acquired 5,620 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average price of $178.05 per share, for a total transaction of $1,000,641.00. Following the completion of the transaction, the chief executive officer now owns 202,643 shares in the company, valued at approximately $36,080,586.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard F. Wallman purchased 1,000 shares of the stock in a transaction dated Thursday, August 24th. The shares were purchased at an average cost of $198.79 per share, for a total transaction of $198,790.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $198,790. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).